MX2022012537A - Entrega transdermica de microdosis de derivados psicodelicos. - Google Patents
Entrega transdermica de microdosis de derivados psicodelicos.Info
- Publication number
- MX2022012537A MX2022012537A MX2022012537A MX2022012537A MX2022012537A MX 2022012537 A MX2022012537 A MX 2022012537A MX 2022012537 A MX2022012537 A MX 2022012537A MX 2022012537 A MX2022012537 A MX 2022012537A MX 2022012537 A MX2022012537 A MX 2022012537A
- Authority
- MX
- Mexico
- Prior art keywords
- psychedelics
- derivatives
- addiction
- treatment
- dosing delivery
- Prior art date
Links
- 230000001337 psychedelic effect Effects 0.000 title abstract 2
- 239000003196 psychodysleptic agent Substances 0.000 title abstract 2
- 208000007848 Alcoholism Diseases 0.000 abstract 1
- 208000019901 Anxiety disease Diseases 0.000 abstract 1
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 abstract 1
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 abstract 1
- 208000006561 Cluster Headache Diseases 0.000 abstract 1
- 208000022497 Cocaine-Related disease Diseases 0.000 abstract 1
- 206010011906 Death Diseases 0.000 abstract 1
- ZAGRKAFMISFKIO-UHFFFAOYSA-N Isolysergic acid Natural products C1=CC(C2=CC(CN(C2C2)C)C(O)=O)=C3C2=CNC3=C1 ZAGRKAFMISFKIO-UHFFFAOYSA-N 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 abstract 1
- 208000026251 Opioid-Related disease Diseases 0.000 abstract 1
- SPCIYGNTAMCTRO-UHFFFAOYSA-N Psilocine Natural products C1=CC(O)=C2C(CCN(C)C)=CNC2=C1 SPCIYGNTAMCTRO-UHFFFAOYSA-N 0.000 abstract 1
- QVDSEJDULKLHCG-UHFFFAOYSA-N Psilocybine Natural products C1=CC(OP(O)(O)=O)=C2C(CCN(C)C)=CNC2=C1 QVDSEJDULKLHCG-UHFFFAOYSA-N 0.000 abstract 1
- VOXIUXZAOFEFBL-UHFFFAOYSA-N Voacangin Natural products CCC1CC2CN3CC1C(C2)(OC(=O)C)c4[nH]c5ccc(OC)cc5c4C3 VOXIUXZAOFEFBL-UHFFFAOYSA-N 0.000 abstract 1
- 230000036506 anxiety Effects 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 201000006145 cocaine dependence Diseases 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 abstract 1
- 206010013663 drug dependence Diseases 0.000 abstract 1
- HSIBGVUMFOSJPD-CFDPKNGZSA-N ibogaine Chemical compound N1([C@@H]2[C@H]3C[C@H](C1)C[C@@H]2CC)CCC1=C3NC2=CC=C(OC)C=C12 HSIBGVUMFOSJPD-CFDPKNGZSA-N 0.000 abstract 1
- OLOCMRXSJQJJPL-UHFFFAOYSA-N ibogaine Natural products CCC1CC2CC3C1N(C2)C=Cc4c3[nH]c5ccc(OC)cc45 OLOCMRXSJQJJPL-UHFFFAOYSA-N 0.000 abstract 1
- AREITJMUSRHSBK-UHFFFAOYSA-N ibogamine Natural products CCC1CC2C3CC1CN2CCc4c3[nH]c5ccccc45 AREITJMUSRHSBK-UHFFFAOYSA-N 0.000 abstract 1
- ZAGRKAFMISFKIO-QMTHXVAHSA-N lysergic acid Chemical compound C1=CC(C2=C[C@H](CN([C@@H]2C2)C)C(O)=O)=C3C2=CNC3=C1 ZAGRKAFMISFKIO-QMTHXVAHSA-N 0.000 abstract 1
- 208000024714 major depressive disease Diseases 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- ZBWSBXGHYDWMAK-UHFFFAOYSA-N psilocin Chemical compound C1=CC=C(O)[C]2C(CCN(C)C)=CN=C21 ZBWSBXGHYDWMAK-UHFFFAOYSA-N 0.000 abstract 1
- QKTAAWLCLHMUTJ-UHFFFAOYSA-N psilocybin Chemical compound C1C=CC(OP(O)(O)=O)=C2C(CCN(C)C)=CN=C21 QKTAAWLCLHMUTJ-UHFFFAOYSA-N 0.000 abstract 1
- 230000009430 psychological distress Effects 0.000 abstract 1
- 230000000391 smoking effect Effects 0.000 abstract 1
- 230000035882 stress Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/48—Ergoline derivatives, e.g. lysergic acid, ergotamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
- A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
- A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
- A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
- A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
- A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
- A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
- A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
- A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
- A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
- A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
- A61K9/7061—Polyacrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Addiction (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La presente divulgación se refiere a la administración transdérmica de psicodélicos, tales como psilocibina, psilocina, dietilamina del ácido lisérgico (LSD) y/o ibogaína, y derivados de estos compuestos, para el tratamiento y/o prevención y/o control de depresión severa (resistente al tratamiento), trastorno depresivo mayor, trastorno obsesivo-compulsivo, dejar de fumar, adicción al alcohol, adicción a la cocaína, adicción a los opiáceos, ansiedad (estrés), TDAH en adultos, dolores de cabeza en grupo y angustia sicológica relacionada con el cáncer u otras enfermedades del final de la vida.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063010924P | 2020-04-16 | 2020-04-16 | |
| PCT/IB2021/000248 WO2021209815A1 (en) | 2020-04-16 | 2021-04-15 | Transdermal micro-dosing delivery of psychedelics derivatives |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2022012537A true MX2022012537A (es) | 2022-11-07 |
Family
ID=78081176
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2022012537A MX2022012537A (es) | 2020-04-16 | 2021-04-15 | Entrega transdermica de microdosis de derivados psicodelicos. |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20210322447A1 (es) |
| EP (1) | EP4135712A4 (es) |
| JP (1) | JP2023520844A (es) |
| CN (1) | CN115916215A (es) |
| AU (1) | AU2021254855A1 (es) |
| CA (1) | CA3173048A1 (es) |
| MX (1) | MX2022012537A (es) |
| WO (1) | WO2021209815A1 (es) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114072945A (zh) * | 2019-05-21 | 2022-02-18 | La药研科技公司 | 用于治疗精神障碍、行为障碍、认知障碍的新型药物组合物和方法 |
| IL291839A (en) | 2019-10-01 | 2022-06-01 | Empyrean Neuroscience Inc | Genetic engineering of fungi to modulate tryptamine expression |
| US11759452B2 (en) | 2020-05-08 | 2023-09-19 | Psilera Inc. | Compositions of matter and pharmaceutical compositions |
| EP4153564A4 (en) | 2020-05-19 | 2024-06-19 | Cybin IRL Limited | DEUTERATED TRYPTAMINE DERIVATIVES AND METHODS OF USE |
| WO2021250434A1 (en) | 2020-06-12 | 2021-12-16 | Beckley Psytech Limited | Composition comprising a benzoate salt of 5-methoxy-n,n-dimethyltryptamine |
| US20220273628A1 (en) * | 2021-02-19 | 2022-09-01 | Universitätsspital Basel | Effects of lysergic acid diethylamide (lsd) and of lsd analogs to assist psychotherapy for generalized anxiety disorder or other anxiety not related to life-threatening illness |
| EP4313007A1 (en) * | 2021-03-31 | 2024-02-07 | Lyfe CHNG, LLC | Transdermal system, formulation, and method for the therapeutic administration of a psychedelic agent |
| US20230039395A1 (en) * | 2021-08-03 | 2023-02-09 | Universitätsspital Basel | Lsd and psilocybin dose equivalence determination |
| US20230059204A1 (en) * | 2021-08-03 | 2023-02-23 | Pike Therapeutics, Inc. | Transdermal micro-dosing delivery of pharmaceutical agents |
| WO2023077245A1 (en) * | 2021-11-08 | 2023-05-11 | Nova Mentis Life Science Corp. | Diagnosing, monitoring and treating neurological disease with psychoactive tryptamine derivatives and mrna measurements |
| WO2023137325A1 (en) * | 2022-01-11 | 2023-07-20 | New York University | Treating alcohol use disorder using psilocybin |
| WO2023135595A1 (en) * | 2022-01-11 | 2023-07-20 | Psyrx Ltd. | Combinations with psilocybin for treating gastrointestinal diseases or disorders |
| WO2023168022A1 (en) | 2022-03-04 | 2023-09-07 | Reset Pharmaceuticals, Inc. | Co-crystals or salts comprising psilocybin |
| GB202212116D0 (en) | 2022-08-19 | 2022-10-05 | Beckley Psytech Ltd | Pharmaceutically acceptable salts and Compositions thereof |
| CN116407557A (zh) * | 2023-05-29 | 2023-07-11 | 四川大学华西医院 | 一种防治出血性脑卒中的药物组合物及其应用 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10960077B2 (en) * | 2006-05-12 | 2021-03-30 | Intellipharmaceutics Corp. | Abuse and alcohol resistant drug composition |
| KR101656537B1 (ko) * | 2008-06-19 | 2016-09-09 | 에르테에스 로만 테라피-시스테메 아게 | 양이온성 활성제의 경피 전달용 조성물 |
| EP2886153A1 (de) * | 2013-12-20 | 2015-06-24 | LTS LOHMANN Therapie-Systeme AG | System für die transdermale Abgabe von Wirkstoff |
| CA3212001A1 (en) * | 2014-03-03 | 2015-09-11 | Demerx, Inc. | Therapeutic uses of ibogaine and related compounds |
| US20150258112A1 (en) * | 2014-03-13 | 2015-09-17 | Demerx, Inc. | Methods and compositions for treating depression using ibogaine |
| EP3268086A4 (en) * | 2015-03-10 | 2018-11-07 | Eleusis Benefit Corporation, PBC | Lsd for the treatment of alzheimer's disease |
| JP7273731B2 (ja) * | 2017-02-09 | 2023-05-15 | カームテック、エルエルシー | シロシビン誘導体を含む組成物及び方法 |
-
2021
- 2021-04-15 CA CA3173048A patent/CA3173048A1/en active Pending
- 2021-04-15 AU AU2021254855A patent/AU2021254855A1/en active Pending
- 2021-04-15 MX MX2022012537A patent/MX2022012537A/es unknown
- 2021-04-15 JP JP2022554771A patent/JP2023520844A/ja active Pending
- 2021-04-15 CN CN202180026573.XA patent/CN115916215A/zh active Pending
- 2021-04-15 WO PCT/IB2021/000248 patent/WO2021209815A1/en unknown
- 2021-04-15 US US17/231,553 patent/US20210322447A1/en not_active Abandoned
- 2021-04-15 EP EP21788033.5A patent/EP4135712A4/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20210322447A1 (en) | 2021-10-21 |
| AU2021254855A1 (en) | 2022-09-15 |
| EP4135712A4 (en) | 2024-04-17 |
| JP2023520844A (ja) | 2023-05-22 |
| CA3173048A1 (en) | 2021-10-21 |
| EP4135712A1 (en) | 2023-02-22 |
| WO2021209815A1 (en) | 2021-10-21 |
| CN115916215A (zh) | 2023-04-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2022012537A (es) | Entrega transdermica de microdosis de derivados psicodelicos. | |
| Ma et al. | The role of mitochondrial dynamics in human cancers | |
| AU2008325608B2 (en) | Combination of anti-angiogenic substance and anti-tumor platinum complex | |
| EP3416964B1 (en) | 6-oxo-n-(1-(benzyl)-1h-pyrazol-4-yl)-6,7,8,9- tetrahydropyrido[3',2':4,5]pyrrolo[1,2-a]pyrazine-2-carboxamide derivatives as p90 ribosomal s6 kinase (rsk) inhibitors for treating cancer | |
| Quan et al. | 8-bromo-7-methoxychrysin inhibits properties of liver cancer stem cells via downregulation of β-catenin | |
| Russo et al. | Impact of genetic variability in nicotinic acetylcholine receptors on nicotine addiction and smoking cessation treatment | |
| CA2445467A1 (en) | Quinuclidines-substituted-multi-cyclic-heteroaryls for the treatment of disease | |
| IE58142B1 (en) | Substituted propane-phosphonous acid compounds | |
| JP2020514409A (ja) | ジアリール大環状化合物を含む併用療法 | |
| RU2587619C2 (ru) | Антагонисты неурегулина и применение их в лечении злокачественного новообразования | |
| Sourbron et al. | Serotonin receptors in epilepsy: Novel treatment targets? | |
| JP2015044847A (ja) | オピオイド拮抗薬とｍＴＯＲ阻害薬を用いた治療 | |
| MX2022011901A (es) | Arilo piperidinas como moduladores de monoacilglicerol lipasa. | |
| MY193754A (en) | Treatment for parkinson's disease | |
| Gwak et al. | Combined action of the dinuclear platinum compound BBR3610 with the PI3‐K inhibitor PX‐866 in glioblastoma | |
| JP2015508099A (ja) | 環状ジアミノピリジン誘導体 | |
| Yin et al. | Inhibition of brain ischemia-caused notch activation in microglia may contribute to isoflurane postconditioning-induced neuroprotection in male rats | |
| JP2001504852A (ja) | 双極性障害の治療のためのｎｋ−１受容体拮抗薬の使用 | |
| RU2005138591A (ru) | Новые производные 8-аза-бицикло{3.2.1}октана и их применение в качестве ингибиторов обратного захвата моноаминовых нейротрансмиттеров | |
| MX2023010087A (es) | Derivados heterociclicos como inhibidores de cinasas jano. | |
| Ongini et al. | Differential effects of dopamine D-1 and D-2 receptor agonists on EEG activity and behaviour in the rabbit | |
| Angelantonio et al. | Donepezil modulates nicotinic receptors of substantia nigra dopaminergic neurones | |
| Park et al. | Low-dose remifentanil to modify hemodynamic responses to tracheal intubation: comparison in normotensive and untreated/treated hypertensive Korean patients | |
| MX2023010083A (es) | Derivados heterociclicos como inhibidores de cinasas jano. | |
| CA2445834C (en) | Dihydroimidazo[4,5-e]indole and 7h-pyrrolo[3,2-f]quinoxaline derivatives as nicotinic acetylcholine receptor ligands and/or serotonergic ligands |